A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease

Literature Review ◽

Bowel Disease ◽

Drug Monitoring ◽

Consensus Statement ◽

Expert Consensus ◽

Therapeutic Drug ◽

Comprehensive Literature Review ◽

PGI7 THE CLINICAL IMPACT OF THERAPEUTIC DRUG MONITORING IN INFLAMMATORY BOWEL DISEASE â”€ A CRITICAL LITERATURE REVIEW AND META-ANALYSIS

Value in Health ◽

10.1016/j.jval.2019.09.1130 ◽

2019 ◽

Vol 22 ◽

pp. S617

Author(s):

M. Povero ◽

L. Pradelli ◽

O. Secchi ◽

A. Brigido ◽

A. Franchi

Keyword(s):

Literature Review ◽

Bowel Disease ◽

Drug Monitoring ◽

Meta Analysis ◽

Clinical Impact ◽

Therapeutic Drug ◽

Inflammatory Bowel ◽

Critical Literature

Therapeutic drug monitoring with vedolizumab in inflammatory bowel disease

Minerva Gastroenterologica e Dietologica ◽

10.23736/s1121-421x.19.02625-4 ◽

2020 ◽

Vol 65 (4) ◽

Author(s):

Daniela Pugliese ◽

Giuseppe Privitera ◽

Fabrizio Pizzolante ◽

Antonio Gasbarrini ◽

Luisa Guidi ◽

...

Keyword(s):

Bowel Disease ◽

Drug Monitoring ◽

Therapeutic Drug ◽

Faculty Opinions recommendation of Therapeutic Drug Monitoring During Induction of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: Defining a Therapeutic Drug Window.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.728770716.793568133 ◽

2019 ◽

Author(s):

Ashish Patel

Keyword(s):

Tumor Necrosis Factor ◽

Bowel Disease ◽

Drug Monitoring ◽

Tumor Necrosis ◽

Therapeutic Drug ◽

Factor Therapy ◽

Inflammatory Bowel ◽

Necrosis Factor

P546 Therapeutic drug monitoring of vedolizumab in inflammatory bowel disease

Journal of Crohn s and Colitis ◽

10.1093/ecco-jcc/jjy222.670 ◽

2019 ◽

Vol 13 (Supplement_1) ◽

pp. S387-S387

Author(s):

N Torres ◽

D Martín Arranz ◽

M Sánchez Azofra ◽

E Martín Arranz ◽

L Garcia ◽

...

Keyword(s):

Bowel Disease ◽

Drug Monitoring ◽

Therapeutic Drug ◽

Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease

Alimentary Pharmacology & Therapeutics ◽

10.1111/apt.12407 ◽

2013 ◽

Vol 38 (5) ◽

pp. 447-459 ◽

Cited By ~ 74

Author(s):

R. Khanna ◽

B. D. Sattin ◽

W. Afif ◽

E. I. Benchimol ◽

E.-J. Bernard ◽

...

Keyword(s):

Bowel Disease ◽

Drug Monitoring ◽

Review Article ◽

Therapeutic Drug ◽

Therapeutic drug monitoring was helpful in guiding the decision-making process for children receiving infliximab for inflammatory bowel disease

Acta Paediatrica ◽

10.1111/apa.14008 ◽

2017 ◽

Vol 106 (11) ◽

pp. 1863-1867 ◽

Cited By ~ 13

Author(s):

Vini Deora ◽

Justin Kozak ◽

Mohamed El-Kalla ◽

Hien Q. Huynh ◽

Wael El-Matary

Keyword(s):

Decision Making ◽

Bowel Disease ◽

Drug Monitoring ◽

Therapeutic Drug ◽

Decision Making Process ◽

Low dose thioguanine guided by therapeutic drug monitoring is a safe and effective alternative in inflammatory bowel disease patients intolerant to conventional thiopurines

Internal Medicine Journal ◽

10.1111/imj.15639 ◽

2021 ◽

Author(s):

A. Eqbal ◽

A. Martin ◽

J.D. Doecke ◽

D. Patrick

Keyword(s):

Bowel Disease ◽

Drug Monitoring ◽

Low Dose ◽

Effective Alternative ◽

Therapeutic Drug ◽

Wide variation in the use and understanding of therapeutic drug monitoring for anti-TNF agents in inflammatory bowel disease: an inexact science?

Expert Opinion on Biological Therapy ◽

10.1080/14712598.2018.1537367 ◽

2018 ◽

Vol 18 (12) ◽

pp. 1271-1279 ◽

Cited By ~ 5

Author(s):

Mark A Samaan ◽

Zehra Arkir ◽

Tariq Ahmad ◽

Peter M Irving

Keyword(s):

Bowel Disease ◽

Drug Monitoring ◽

Therapeutic Drug ◽

Clinical value and cost saving of therapeutic drug monitoring of infliximab in adult patients with inflammatory bowel disease

Clinical Medicine ◽

10.7861/clinmed.20-2-s23 ◽

2020 ◽

Vol 20 (Suppl 2) ◽

pp. s23-s24

Author(s):

Sashiananthan Ganesananthan ◽

Dharmaraj Durai

Keyword(s):

Cost Saving ◽

Bowel Disease ◽

Drug Monitoring ◽

Adult Patients ◽

Therapeutic Drug ◽

Clinical Value ◽

Faculty Opinions recommendation of Proactive therapeutic drug monitoring of adalimumab is associated with better long-term outcomes compared to standard of care in patients with inflammatory bowel disease.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.734938397.793562770 ◽

2019 ◽

Author(s):

Sara McCartney

Keyword(s):

Bowel Disease ◽

Drug Monitoring ◽

Standard Of Care ◽

Therapeutic Drug ◽

Long Term Outcomes ◽